Article Text

SAT0282 Clinical and Laboratory Characteristics Associated with Visual Complications in Patients with Biopsy-Proven GIANT Cell Arteritis
  1. M. Saleh1,
  2. C. Turesson2,
  3. M. Englund3,4,
  4. P.A. Merkel5,
  5. A.J. Mohammad6,7
  1. 1Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital, Helsingborg
  2. 2Department of Clinical Sceinces, Section of Rheumatology, Lund University, Malmö
  3. 3Department of Orthopedics, Lund University, Lund, Sweden
  4. 4Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston
  5. 5Division of Rheumatology, University of Pennsylvania, Philadelphia, United States
  6. 6Department of Clinical Sceinces, Section of Rheumatology, Lund University, Lund, Sweden
  7. 7Department of Renal Medicine, Vasculitis and Lupus Clinic, Cambridge University Hospitals, Cambridge, United Kingdom


Background Early diagnosis of giant cell arteritis (GCA) and prompt initiation of high-dose glucocorticoid treatment is important to avoid permanent organ damage. One of the most feared outcomes in GCA are ischemic complications, especially visual impairment or irreversible blindness.

Objectives To compare the clinical and laboratory characteristics of patients with biopsy-proven GCA who develop visual complications to patients with GCA with no visual complications.

Methods Data from 840 patients with biopsy-proven GCA in Skåne, the southernmost region in Sweden, diagnosed between 1997 and 2010, were used for this analysis. Patients with GCA were identified in the regional register of the Department of Pathology in Skåne using established methods[1].The occurrences of acute visual complications after the onset of GCA were identified by linking the GCA cohort to the Skåne Health care Register as previously described using the ICD-10 codes[2]. A nested case-control study was performed within the GCA cohort in which cases with visual complication were compared to age- and sex-matched patients with GCA without visual complications. In a structured review of all medical records, the presence of ophthalmological disease was validated, and we also recorded the use of selected medications at GCA onset, and histopathology findings (Table).

Results 100 of the 840 patients (12%) with GCA had an assigned diagnosis code for at least one visual complication. Upon detailed case record review, eight patients with an ophthalmological complication that pre-dated the diagnosis of GCA, and seven cases with either incomplete records or incorrectly assigned ICD codes were excluded. 85 patients were found to have visual complications (10% of patients); 72 patients had unilateral and 13 had bilateral visual impairment. Compared to patients without visual impairment, patients with GCA with new-onset visual impairment were less likely to have headache, fever, palpable abnormal temporal artery, polymyalgia rheumatica, and lower CRP at diagnosis compared with controls. The use of beta-blockers was associated with visual complication (Table).

Conclusions Patients with GCA with visual complications as a group have lower inflammatory responses compared to patients with GCA and no visual problems, a finding similar to what has been shown in previous studies. Patients with visual complications are more likely to be treated with beta-blockers than patients with GCA without visual changes. The role of beta-blockers in end-organ ischemia related to GCA should be further studied.


  1. Mohammad AJ et al. Ann Rheum Dis. 2014 Jan 17. doi: 10.1136/annrheumdis-2013-204652. [Epub ahead of print]

  2. Bremander A et al. Arthritis Care Res (Hoboken). 2011 Apr; 63(4):550-556.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3018

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.